Allogeneic Cell Therapies Market Revenue (US$ Mn) by Type of Cell Therapy
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Source of Cell
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Target Indication
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Therapeutic Area
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Region
Chapter 1.Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2.Executive Summary
Chapter 3.Global Allogeneic Cell Therapy Market Snapshot
Chapter 4.Global Allogeneic Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5.Market Segmentation 1: By Type of Cell Therapy Estimates & Trend Analysis
5.1. By Type of Cell Therapy & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Type of Cell Therapy:
5.2.1. Virus-Specific T-Cell
5.2.2. Stem Cell
5.2.3. Regulatory T-Cell
Chapter 6.Market Segmentation 2: By Source of Cell Estimates & Trend Analysis
6.1. By Source of Cell & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Source of Cell:
6.2.1. Peripheral Blood
6.2.2. Bone Marrow
6.2.3. Umbilical Cord Blood
6.2.4. Adipose Tissue
6.2.5. Placenta
Chapter 7.Market Segmentation 3: By Target Indication Estimates & Trend Analysis
7.1. By Target Indication & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Target Indication:
7.2.1. Bone Disorder
7.2.2. Critical Limb Ischemia
7.2.3. Crohn’s Disease
7.2.4. Diabetic Foot Ulcer
7.2.5. Graft versus Host Disease
7.2.6. Leukemia
7.2.7. Lymphoma
7.2.8. Myelodysplastic Syndrome
7.2.9. Cytomegalovirus Infection
7.2.10. Others
Chapter 8.Market Segmentation 3: By Therapeutic Area Estimates & Trend Analysis
8.1. By Therapeutic Area & Market Share, 2019-2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Therapeutic Area:
8.2.1. Oncological Disorders
8.2.2. Neurological Disorders
8.2.3. Musculoskeletal Disorder
8.2.4. Autoimmune / Inflammatory Disorders
8.2.5. Post-Transplant Infections
Chapter 9.Allogeneic Cell Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Type of Cell Therapy, 2023-2031
9.1.2. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.1.3. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.1.4. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.1.5. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.2.2. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.2.3. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.2.4. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.2.5. Europe Allogeneic Cell Therapy Market revenue (US$ Million) by country, 2023-2031
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.3.2. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.3.3. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.3.4. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.3.5. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) by country, 2023-2031
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.4.2. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.4.3. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.4.4. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.4.5. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, (US$ Million)
9.5.2. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.5.3. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.5.4. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.5.5. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA
Chapter 10.Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. TCR² Therapeutics
10.2.2. TiGenix (Takeda)
10.2.3. Adaptimmune Therapeutics plc,
10.2.4. Adicet Bio, Inc.,
10.2.5. Allogene Therapeutics,
10.2.6. Allogene Therapeutics,
10.2.7. Artiva Biotherapeutic,
10.2.8. Atara Biotherapeutics,
10.2.9. Athersys, Inc.,
10.2.10. BioCardia Inc.,
10.2.11. Bluebird Bio,
10.2.12. BlueRock Therapeutics LP,
10.2.13. Bone Therapeutics,
10.2.14. Capricor Therapeutics,
10.2.15. Cell2Cure,
10.2.16. Cellectis,
10.2.17. Cellenkos,
10.2.18. Cellular Biomedicine Group,
10.2.19. Celularity,
10.2.20. Celyad,
10.2.21. Century Therapeutics,
10.2.22. CHABiotech,
10.2.23. CRISPR Therapeutics,
10.2.24. Cynata Therapeutics,
10.2.25. Cyto Therapeutics Pty Limited,
10.2.26. Fate Therapeutics,
10.2.27. Fate Therapeutics,
10.2.28. Fundamenta Therapeutics,
10.2.29. GammaDelta Therapeutics Limited,
10.2.30. GC Cell,
10.2.31. Hope Biosciences,
10.2.32. Immunity Bio,
10.2.33. Lineage Cell Therapeutics, Inc.,
10.2.34. MEDIPOST,
10.2.35. Mesoblast Ltd,
10.2.36. Nanjing Bioheng Biotech,
10.2.37. NantKwest,
10.2.38. Nkarta, Inc.,
10.2.39. Orca Bio,
10.2.40. Organogenesis Inc.,
10.2.41. Osiris Therapeutics, Inc.,
10.2.42. Pluristem Therapeutics Inc,
10.2.43. Poseida Therapeutics
10.2.44. Regeneus,
10.2.45. Stemedica Cell Technologies, Inc.,
10.2.46. Stempeutics
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.